A Study of ARRY-334543 in Patients With Advanced Cancer

NCT00278902 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: ARRY-334543, EGFR/ErbB2 inhibitor; oral

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer